Roumell Asset Management’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Roumell Asset Management’s Portfolio ARDS Stock Details ARDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-446,588	Closed	-$98.2K	–	24
2023 Q2	$98.2K	Hold	446,588	–	–	0.19%	22
2023 Q1	$140K	Hold	446,588	–	–	0.32%	19
2022 Q4	$527K	Hold	446,588	–	–	1.3%	18
2022 Q3	$415K	Hold	446,588	–	–	0.9%	20
2022 Q2	$491K	Hold	446,588	–	–	0.96%	21
2022 Q1	$786K	Hold	446,588	–	–	1.27%	19
2021 Q4	$1.04M	Buy	446,588 +99,071	+29%	+$282K	1.39%	18
2021 Q3	$1.28M	Buy	347,517 +74,631	+27%	+$345K	1.69%	13
2021 Q2	$2.02M	Buy	272,886 +50,664	+23%	+$316K	2.36%	14
2021 Q1	$1.31M	Buy	+222,222	New	+$1.5M	1.9%	14

Other funds holding ARDS

Wealth Architects Mountain View, California $1.27B AUM 36.93% 1-Year Est. Return

Roumell Asset Management's ARDS Position: Q3 2023 in Review

Roumell Asset Management sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 446,588 shares — an estimated $98.2K sold.

Roumell Asset Management first reported a position in ARDS in Q1 2021 and held it in 10 quarters. The position peaked at $2.02M in Q2 2021. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.

Roumell Asset Management reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Roumell Asset Management sold 446,588 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $98.2K.
Roumell Asset Management first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Roumell Asset Management's Aridis Pharmaceuticals Inc. Common Stock position peaked at $2.02M in Q2 2021.
1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.

Based on Roumell Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.